In view of a clinical suspicion, the diagnosis can be made with brain evoked response audiometry (BERA). 2, 4 In these cases, the hearing loss should be differentiated from lupus dysacousia, characterized by sudden or rapidly progressing neurosensory hypoacusis, with reduced response on the audiometry evaluations.
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Inflammatory tests and the presence of antibodies will help in the differentiation. 5 There are reports in the literature of partial improvement after early therapy with steroids and vasodilators. 3, 4 The drugs used have anti-inflammatory effects and could control the hypersensitivity reaction of the vessels to antimalarials, restoring the blood supply for the inner ear. 3, 4 Thus, one must be vigilant regarding any sign or symptom related to hearing changes in patients using these medications, so that the diagnosis can be made early enough to allow for the reversal of the picture. Although rare, HCQ ototoxicity is a severe complication that impairs functional activities and quality of life of the patients and can appear after relatively short periods of use and in low doses. With this study, we aim to alert for the ototoxic potential of the antimalarials and suggest that patients be carefully advised about this complication when they start treatment. We also suggest a periodic audiology assessment of the patients using antimalarials for a prolonged and regular period so that eventual ototoxic changes can be detected early, therefore avoiding possible irreversible damage. q Once the anti-inflammatory was withdrawn, the patient showed significant clinical improvement, which allowed the corticosteroid and azathioprine to be discontinued. In order to confirm the diagnosis, the patient was submitted to patch tests with Brazilian's standard and cosmetic battery, as well as 1%, 5% and 10% nimesulide in vaseline. Since nimesulide is not available for patch tests in Brazil, the drug was manipulated to fit the criteria described above. Both the drug concentrations and the vehicle used were obtained from the literature. 1 The drug was applied on the skin of both the patient's back and on residual lesions on the lower limbs.
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Among the standard substances used, patch tests were positive for cobalt chloride (+++) and nickel sulfate (++); among the nimesulide concentrations used, patch tests were positive only for those applied on residual lesions at both 5% and 10% ( Figure 3 ).
The diagnosis of fixed drug eruption relies on a thorough medical history as it allows the correlation between clinical symptoms and drug use. The anatomopathological exam is not specific.
Although reexposure tests are considered gold-standard for diagnosis, the harmful effects caused can be avoided by performing patch tests. [1] [2] [3] Patch test efficiency can be variable, however it does yield good results for cases induced by nonsteroidal anti-inflammatory drugs (NSAIDs). 1, 2 Given that the pathophysiology of fixed drug eruption is most likely related to the persistence of memory T cells on affected regions of the skin, patch tests can be improved by applying the suspected drug on residual lesions. 1,2 False negative tests are most likely caused by a reduced drug absorption through stratum corneum or the inability of of the original form of the drug to activate the immune system, which would be accomplished only by systemic metabolization into immunologically active metabolites. 1 The most common cutaneous side effects of nimesulide are itching and exanthema. However, few case reports of fixed drug eruption associated to nimesulide have been published, and even less showing mucous involvement. 4, 5 The most effective intervention is discontinuing the drug. Nimesulide may present crossed-reactions to sulfonamides and to other COX-2 enzyme inhibitors, and thus their use should be avoided or preceeded by therapeutic testing. 4 We report the diagnostic challenges related to the exuber- Histopathology revealed a proliferation of blood vessels Marília Gabriela Senra Torre 0000-0001-5151-3736
